Clinical trial
Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138
NCT01886976 · Chinese PLA General Hospital, Other · Unknown status
Key facts
| NCT number | NCT01886976 |
|---|---|
| Title | Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138 |
| Official title | Clinical Study of Chimeric CD(Cluster of Differentiation)138 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Multiple Myelomas |
| Acronym | CART-138 |
| Lead sponsor | Chinese PLA General Hospital, Other |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Biological |
| Interventions | CART-138 cells |
| Enrollment | 10 |
| Start date | Jun 1, 2013 |
| Primary completion | Jun 1, 2016 |
| Completion | Jun 1, 2016 |
| First posted | Jun 26, 2013 |
| Last update posted | Jan 28, 2016 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: